NCI-H28Homo sapiens (Human)Cancer cell line
Also known as: HuT28, Hut28, HUT28, HuT 28, HUT 28, HUT-28, NCIH28, H-28, H28
Quick Overview
Malignant mesothelioma cell line with known genetic alterations
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_1555 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
Age | 48 |
---|---|
Age Category | Adult |
Sex | Male |
Race | caucasian |
Disease Information
Disease | Pleural mesothelioma |
---|---|
Lineage | Pleura |
Subtype | Pleural Mesothelioma, Epithelioid Type |
OncoTree Code | PLEMESO |
DepMap Information
Source Type | ATCC |
---|---|
Source ID | ACH-000648_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | VHL | p.Leu89His (c.266T>A) | Unspecified | - | PubMed=7915601 |
MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
MutationSimple | BAP1 | p.Arg146Alafs*48 (c.438-24_438-2del23) | Homozygous | - | PubMed=26011428, PubMed=21642991 |
Gene deletion | CTNNB1 | - | Homozygous | - | PubMed=11464291, PubMed=11070089 |
Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.
Kato T., Sato T., Yokoi K., Sekido Y.
Oncogene 36:5522-5531(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.
Yokoi K., Sekido Y.
Cancer Sci. 106:990-999(2015).
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Asamura H., Gemma A., Yamada T.
J. Thorac. Oncol. 10:844-851(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
Rice D.C., Tsao A., Wistuba I.I.
J. Thorac. Oncol. 9:998-1007(2014).
Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.
Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.
Cancer Genet. 206:191-205(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.
Nat. Genet. 43:668-672(2011).
LATS2 is a tumor suppressor gene of malignant mesothelioma.";
Sekido Y.
Cancer Res. 71:873-883(2011).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.
Sekido Y.
Cancer Sci. 98:438-446(2007).
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.
Cancer Sci. 97:387-394(2006).
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion.
Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K.
Oncogene 20:4249-4257(2001).
Altered HOX and WNT7A expression in human lung cancer.";
Gemmill R.M., Drabkin H.A.
Proc. Natl. Acad. Sci. U.S.A. 97:12776-12781(2000).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
NCI-Navy Medical Oncology Branch cell line data base.";
Carney D.N., Minna J.D., Mulshine J.L.
J. Cell. Biochem. Suppl. 24:32-91(1996).
Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines.
Zbar B., Lerman M.I., Minna J.D.
Oncogene 9:1599-1604(1994).
High levels of intracellular bombesin characterize human small-cell lung carcinoma.
Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.
Science 214:1246-1248(1981).
p53 and Kirsten-ras mutations in human mesothelioma cell lines.";
Harris C.C.
Cancer Res. 52:2610-2615(1992).